One of Japan's largest pharmaceutical companies, headquartered in Osaka, with roots dating back to a 1717 apothecary; develops and markets pharmaceuticals and diagnostic reagents, notably the cancer immunotherapy nivolumab (Opdivo).
相关临床试验
153
37 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1948
进行中（未招募）
34
22.2%
已完成
83
54.3%
尚未招募
3
2.0%
招募中
25
16.3%
暂停
2
1.3%
终止
6
3.9%
暂无批准数据
- Bristol Myers Squibb and Ono Pharmaceutical filed suit in Delaware federal court seeking to block Amgen's proposed US biosimilar of the cancer immunotherapy Opdivo. - The complaint alleges Amgen's biosimilar would infringe seven US patents covering Opdivo and asks the court to bar sales while those patents remain in force. - Opdivo generated more than $5.9 billion in US revenue last year, and Bristol Myers expects patent exclusivity over the drug to run until 2028. - Amgen declined to comment on the litigation but said it has applied for FDA approval and remains confident it will be in the first wave of Opdivo biosimilars.
- Ono Pharmaceutical and Aitia announced a drug discovery partnership on September 2, 2026, focused on neurological diseases with high unmet medical need. - Aitia will use its causal AI-based REFS™ technology to build Gemini Digital Twins that identify novel therapeutic targets and biomarkers. - Ono gains exclusive worldwide option rights to research, develop, and commercialize drug candidates against targets identified by Aitia. - The collaboration aims to uncover disease mechanisms that conventional correlation-based AI cannot identify in the complex neurology field.
- Mediar Therapeutics and Ono Pharmaceutical have entered a collaboration and option agreement to develop novel antibody therapeutics targeting fibro-inflammatory diseases. - Ono will leverage Mediar's fibrosis-focused discovery platform and myofibroblast expertise, receiving an exclusive option to license worldwide development and commercialization rights. - Mediar continues to independently advance its pipeline, including Phase 2 trials of MTX-474 for systemic sclerosis and MTX-463 for idiopathic pulmonary fibrosis. - The collaboration underscores growing recognition that directly targeting the myofibroblast can unlock new therapeutic possibilities across a broad range of fibrotic diseases.
- Deciphera Pharmaceuticals, a member of Ono Pharmaceutical, announced the first patient dosed in the global pivotal Phase 3 INTREPID study of sapablursen in polycythemia vera. - The trial compares sapablursen to placebo over a 32-week double-blind period, followed by up to 124 weeks of open-label treatment, with phlebotomy-free response as the primary endpoint. - Sapablursen, designed to reduce TMPRSS6 and raise hepcidin, holds FDA Fast Track and Orphan Drug designations from 2024 and Breakthrough Therapy Designation from 2025. - Ono obtained exclusive global development and commercialization rights to sapablursen from Ionis Pharmaceuticals under a license agreement signed in March 2025.
- Japan ranks among the top global pharmaceutical markets and leads in basic life sciences, yet its domestic biotech startup sector lags far behind the US and China, with only 679 biomedical startups as of June 2025. - Japanese venture capital investment in biotech reached just $913 million in 2023, approximately 3% of US levels, severely limiting the ability of startups to advance clinical pipelines. - Large pharmaceutical companies like Takeda and Astellas dominate talent and innovation, while the lifetime employment system and conservative capital markets stifle entrepreneurial risk-taking. - Government reforms including the Startup Development Five-Year Plan and Bio Policy Action Plan aim to redirect resources toward startups, but bridging the ecological gap will require long-term cultivation.
- Inhibrx Biosciences has attracted interest from Merck & Co, Merck KGaA, and Ono Pharmaceutical for its experimental cancer drug INBRX-106, potentially valued at over $8 billion. - INBRX-106 is designed to boost Keytruda's efficacy, with preliminary Phase 2/3 trial data showing improved response rates from 30% to 45% when combined with the immunotherapy. - The biotech is exploring a joint spin-off of INBRX-106 and ozekibart, with combined potential value exceeding $9 billion if clinical trials succeed. - Multiple top-tier pharmaceutical companies including Eli Lilly, AstraZeneca, Pfizer, and J&J are reportedly interested in the immuno-oncology asset.
- Ono Pharmaceutical expanded its collaboration with Congruence Therapeutics in March 2026 to include neurology and immunology drug discovery, extending beyond their previous oncology focus. - The company secured exclusive worldwide option rights over small molecule candidates developed through Congruence's Revenir computational platform in these new therapeutic areas. - Ono also partnered with Sinopia Biosciences on rare metabolic disorders while implementing operational changes including transferring Forxiga distribution back to AstraZeneca. - These strategic moves represent Ono's broader push to diversify its pipeline into areas of significant unmet medical need through AI-driven external collaborations.
- Ligachem Bioscience received a development milestone payment from Japan's Ono Pharmaceutical following successful progress in their ADC platform technology transfer agreement signed in October 2024. - The milestone follows the completion of first target designation in March 2025 and demonstrates that Ligachem's proprietary "Conjugall" ADC platform meets global pharmaceutical development standards. - The achievement validates the scalability and competitiveness of Ligachem's ADC technology, with additional milestones expected from multiple global partnerships throughout 2026.
- Scenic Biotech announced a license and research agreement with Ono Pharmaceutical to utilize its Cell-Seq platform for discovering novel therapeutic targets. - This collaboration represents Scenic's fourth Cell-Seq partnership with a major pharmaceutical company, joining existing agreements with Genentech, Bristol Myers Squibb, and Alnylam. - The partnership validates Scenic's modifier therapy approach, which targets secondary genes to rebalance health rather than addressing primary disease-causing mutations directly.
- Korean pharmaceutical and biotech companies achieved record technology export deals worth 18.111 trillion won ($13.5 billion) in 2024, surpassing the previous 2021 record of 13.8 trillion won. - Platform technologies from companies like ABL Bio, Alteogen, and LigaChem Biosciences accounted for approximately 13 trillion won of these deals, demonstrating their ability to license to multiple global partners. - ABL Bio's blood-brain barrier platform secured major deals with GSK (4.1 trillion won) and Eli Lilly (3.8 trillion won), while Alteogen's subcutaneous injection technology attracted partnerships with AstraZeneca, Merck, and Daiichi Sankyo. - Industry experts note that platform technologies offer "low risk, high return" potential compared to single drug development, requiring less R&D investment while generating early-stage licensing revenue.
